Longeveron Inc. Files Amendment to Annual Report on Form 10-K

TL;DR

<b>Longeveron Inc. has filed an amendment to its 2023 10-K report, providing updated information for its fiscal year ending December 31, 2023.</b>

AI Summary

Longeveron Inc. (LGVN) filed a Amended Annual Report (10-K/A) with the SEC on March 11, 2024. Longeveron Inc. filed an amendment (Amendment No. 1) to its annual report on Form 10-K for the fiscal year ended December 31, 2023. The company is incorporated in Delaware and its principal executive offices are located in Miami, Florida. Longeveron Inc. is registered with the SEC under file number 001-40060. The company's common stock, par value $0.001, is traded under the symbol LGVN on The Nasdaq Capital Market. Longeveron Inc. is classified as a non-accelerated filer and a smaller reporting company.

Why It Matters

For investors and stakeholders tracking Longeveron Inc., this filing contains several important signals. This amendment indicates that Longeveron Inc. is making adjustments or providing additional details to its previously filed annual report, which could impact investor understanding of its financial and operational status. As a non-accelerated filer and smaller reporting company, Longeveron Inc. is subject to different disclosure requirements than larger companies, which is important for investors to consider when evaluating the filing.

Risk Assessment

Risk Level: low — Longeveron Inc. shows low risk based on this filing. The filing is an amendment to a 10-K, which is a routine update and does not inherently signal new risks, but rather provides clarification or correction to existing information.

Analyst Insight

Review the specific changes made in Amendment No. 1 to the 10-K filing to understand any updated disclosures regarding Longeveron Inc.'s financial performance, operations, or risk factors.

Key Numbers

• 2023 — Fiscal Year End (Fiscal year ended December 31, 2023)
• 001-40060 — Commission File Number (SEC File Number)
• LGVN — Trading Symbol (Common Stock Trading Symbol)
• 33136 — ZIP Code (Principal Executive Offices ZIP Code)

Key Players & Entities

• Longeveron Inc. (company) — Registrant
• Delaware (location) — State of Incorporation
• Miami, Florida (location) — Address of Principal Executive Offices
• 001-40060 (other) — Commission File Number
• LGVN (ticker) — Trading Symbol
• The Nasdaq Capital Market (company) — Name of each exchange on which registered
• 20231231 (date) — Fiscal year end
• 20240311 (date) — Filing Date

FAQ

Industry Context

Longeveron Inc. operates in the pharmaceutical preparations industry, focusing on the development of cellular therapies.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, requiring public companies to submit regular financial and operational disclosures to the SEC.

What Investors Should Do

1. Analyze the specific amendments made in this 10-K/A filing.
2. Review Longeveron Inc.'s business description and risk factors for any changes.
3. Monitor future filings for continued updates on the company's progress and financial health.

Year-Over-Year Comparison

This filing is an amendment to the previously submitted 10-K for the fiscal year 2023, indicating updates or corrections to the initial report.

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 LGVN The Nasdaq Capital Market Indica

Filing Documents

• ea0201525-10ka1_longever.htm (10-K/A) — 232KB
• ea020152501ex31-1_longeveron.htm (EX-31.1) — 10KB
• ea020152501ex31-2_longeveron.htm (EX-31.2) — 14KB
• ea020152501ex32-1_longeveron.htm (EX-32.1) — 4KB
• ea020152501ex32-2_longeveron.htm (EX-32.2) — 4KB
• image_001.jpg (GRAPHIC) — 2KB
• image_002.jpg (GRAPHIC) — 2KB
• image_003.jpg (GRAPHIC) — 2KB
• 0001213900-24-021391.txt (&nbsp;) — 581KB
• lgvn-20231231.xsd (EX-101.SCH) — 3KB
• lgvn-20231231_def.xml (EX-101.DEF) — 19KB
• lgvn-20231231_lab.xml (EX-101.LAB) — 39KB
• lgvn-20231231_pre.xml (EX-101.PRE) — 20KB
• ea0201525-10ka1_longever_htm.xml (XML) — 9KB

Business

Item 1. Business Overview We are a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company's lead investigational product is Lomecel-B, an allogeneic Mesenchymal Stem Cell ("MSC") formulation sourced from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action that promote tissue repair and healing with broad potential applications across a spectrum of disease areas. The underlying mechanism(s) of action that may lead to the tissue repair programs include the stimulation of new blood vessel formation, modulation of the immune system, reduction in tissue fibrosis, and the stimulation of endogenous cells to divide and increase the numbers of certain specialized cells in the body. We are currently pursuing three pipeline indications: Hypoplastic Left Heart Syndrome ("HLHS"), Alzheimer's disease ("AD") and Aging-related Frailty. Our mission is to advance Lomecel-B and other cell-based product candidates into pivotal or Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization, and broad use by the healthcare community. In November of 2023, Longeveron received notice from the World Health Organization ("WHO") that "laromestrocel" has been selected as the proposed International Nonproprietary Name for Longeveron's Lomecel-B product. Assuming that there are no third-party objections to that name, the name will be recommended for adoption by the WHO. Longeveron will adopt that name if it is recommended by the WHO. HLHS Our HLHS program is focused on the potential clinical benefits of Lomecel-B as an adjunct therapeutic to standard-of-care HLHS surgery. HLHS is a rare and devastating congenital heart defect in which the left ventricle is severely underdeveloped. As such, babies born with this condition die shortly after birth without undergoing a complex series of reconstructive heart surgeries. Despite the availability of life

View Full Filing

View this 10-K/A filing on SEC EDGAR